Exenatide is a GLP-1 receptor agonist released from the gut and acts to increase glucose-dependent insulin secretion from pancreatic beta cells, suppress glucagon secretion, delay gastric emptying, and reduce food intake. The binding of the drug to pancreatic GLP-1 receptors mediates these actions.
It is an incretin mimic that acts as an agonist at glucagon-like peptide 1 (GLP-1) receptor. It increases glucose-dependent insulin secretion by the pancreatic β-cells, suppresses inappropriately elevated glucagon secretion, increases β-cell growth/replication, and slows gastric emptying. It also decreases food intake by reducing appetite and increasing satiety.
It is an incretin mimic that acts as an agonist at glucagon-like peptide 1 (GLP-1) receptor. It increases glucose-dependent insulin secretion by the pancreatic β-cells, suppresses inappropriately elevated glucagon secretion, increases β-cell growth/replication, and slows gastric emptying. It also decreases food intake by reducing appetite and increasing satiety.
© 2025[current_year] The Doctors Platform. All Right Reserved.
© 2025 The Doctors Platform. All Right Reserved.
